Kardigan, Inc. (KARD) Stock Score, Valuation & Financial Research

Kardigan, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KARD

Kardigan, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 14.22. These figures are a research snapshot, not a buy or sell recommendation.

What Kardigan, Inc. does

Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kardigan is a clinical-stage precision therapeutics company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel cardiovascular medicines, funded through capital raises and equity offerings to support clinical trials and drug discovery operations.

Products and services

  • The company is developing a pipeline of precision therapeutics targeting cardiovascular diseases, including its lead candidate Danicamtiv for dilated cardiomyopathy (DCM).

Brands and product families

  • Danicamtiv — Lead clinical-stage therapeutic candidate for the treatment of dilated cardiomyopathy. Source

Customer types

Patients with cardiovascular diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes unnamed third-party contract research organizations to conduct clinical trials and research activities. Source

Business strengths to evaluate

  • Experienced management team in cardiovascular drug discovery Source
  • Integrated approach using real-world patient data and advanced analytics Source

Business risks and research considerations

  • Clinical-stage status with no approved products or commercial revenue Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source

Sources: Company research source · Danicamtiv

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KARD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 14.22
Market capitalization:
1.27B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -191.94M
Free cash flow:
USD -157.7M
Cash:
USD 384.01M
Total debt:
USD 13.35M
EPS:
USD -3.20

What stands out

  • Free cash flow is USD -157.7M, negative for the stored period.
  • The balance sheet shows USD 384.01M of cash versus USD 13.35M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 370.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KARD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KARD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KARD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KARD to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of KARD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research KARD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.